Literature DB >> 12154210

A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

D Erkan1, Y Yazici, M G Peterson, L Sammaritano, M D Lockshin.   

Abstract

OBJECTIVE: Antiphospholipid antibodies (aPL) are major risk factors for thrombosis. Other clinical factors exist in antiphospholipid syndrome (APS) patients which may have an additive or preventive effect on thrombosis. We therefore performed a cross-sectional study to analyse additive clinical thrombotic risk factors and possible preventive treatments in APS patients, and to compare the results with those obtained in asymptomatic aPL-positive (no history of vascular thrombosis or pregnancy morbidity) patients.
METHODS: We identified 77 APS patients with non-gravid thrombotic events (group A) and 56 asymptomatic aPL-positive patients (group B). The study periods were defined as 6 months prior to the time of first vascular event in group A and 6 months prior to the patient's last visit in group B. Medical records were reviewed to evaluate the incidence of hypertension, diabetes mellitus, hypercholesterolaemia, regular cigarette smoking, oral contraceptive use or hormone replacement therapy, surgical procedures, pregnancy with or without an APS-related event, malignancy and infections. In addition, any history of thrombocytopenia or the use of aspirin, hydroxychloroquine, corticosteroids or immunosuppressives during the study periods was recorded. Bivariate statistical analysis and logistic regression tests were performed to compare groups.
RESULTS: In group A, 75% (n=58) of patients and in group B 48% (n=27) of patients had at least one of the additional risk factors during the study periods. In the bivariate analysis, pregnancy (P=0.005) and surgical procedures (P=0.04) were significantly more frequent in group A, while aspirin (P<0.001), hydroxychloroquine (P<0.001) and corticosteroids (P=0.002) were used significantly more frequently in group B. In logistic regression, the probability of an event was decreased by taking aspirin and/or hydroxychloroquine. In women only, the probability of an event was increased with thrombocytopenia and pregnancy or surgical procedures. The incidences of hypertension and smoking and the presence of more than one risk factor were significantly associated with arterial thrombosis but not venous thrombosis.
CONCLUSION: While traditional risk factors were similar between groups, pregnancy and surgical procedures increased the risk of thrombosis. Hypertension and smoking were associated with arterial events. Possessing a combination of risk factors may increase the occurrence of arterial thrombosis but not venous thrombosis. Use of aspirin and/or hydroxychloroquine may be protective against thrombosis in asymptomatic aPL-positive individuals.

Entities:  

Mesh:

Year:  2002        PMID: 12154210     DOI: 10.1093/rheumatology/41.8.924

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  70 in total

Review 1.  Recurrent miscarriage, antiphospholipid antibodies and the risk of thromboembolic disease.

Authors:  M Ángeles Martínez-Zamora; Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2012-12       Impact factor: 8.667

2.  Analysis of risk factors and comorbid diseases in the development of thrombosis in patients with anticardiolipin antibodies: comment on the article by Sairam et al.

Authors:  Doruk Erkan; Yusuf Yazici
Journal:  Clin Rheumatol       Date:  2003-10-15       Impact factor: 2.980

3.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

Review 4.  Treatment of the antiphospholipid antibody syndrome.

Authors:  Christopher Wu; Kenneth Kalunian
Journal:  Curr Rheumatol Rep       Date:  2004-12       Impact factor: 4.592

5.  Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Susan R Kahn; Wendy Lim; Andrew S Dunn; Mary Cushman; Francesco Dentali; Elie A Akl; Deborah J Cook; Alex A Balekian; Russell C Klein; Hoang Le; Sam Schulman; M Hassan Murad
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 6.  Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.

Authors:  Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

7.  Catastrophic antiphospholipid syndrome triggered by sepsis.

Authors:  Susan Kim; Neal K Moskowitz; Edward F DiCarlo; Anne R Bass; Doruk Erkan; Michael D Lockshin
Journal:  HSS J       Date:  2008-12-19

8.  Antiphospholipid antibodies and sub-clinical atherosclerosis in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort.

Authors:  Darcy S Majka; Kiang Liu; Richard M Pope; Elizabeth W Karlson; Thanh-Huyen T Vu; Marius Teodorescu; Rowland W Chang
Journal:  Inflamm Res       Date:  2013-10       Impact factor: 4.575

9.  Top 10 clinical research developments in antiphospholipid syndrome.

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

10.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.